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chromosomes are organized into discrete chromosome
territories in the interphase nucleus. Genes that are tran-
scriptionally active or poised for activation often loop
away from the chromosome territory to associate with
sites that are rich in transcription factors, and such
changes in subnuclear environment, directed by en-
hancers and locus control regions (Ragoczy et al., 2003),
may themselves influence locus chromatin structure.
Finally, although not directly addressed by the au-
thors, there may be more than one step in locus activa-
tion that is dependent on Eb-PDb1 interaction. Oestreich
et al. (2006) note that, although Jb accessibility is sub-
stantial on the DPDb1 allele, it is reduced by about 50%
compared to wild-type. Perhaps, in addition to locally
disrupting chromatin structure at Db1, Eb-PDb1 interac-
tion can potentiate accessibility at the downstream Jb
segments due to transcriptional elongation by RNA pol
II and associated chromatin remodeling factors (Kristju-
han and Svejstrup, 2004). In summary, chromatin remod-
eling across the Db and Jb segments may be multi-
layered, with Jb segments initially modified by Eb as it
directs a change in subnuclear environment and then
reels in PDb1 and with Eb-PDb1 interaction finally crack-
ing open Db1, stimulating transcription, and, as a conse-
quence, enhancing access to Jb segments. Although
many pieces of the accessibility puzzle still remain, it may
be at the TCRb locus where they are finally assembled.
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363PGRP-LB Minds the Fort
Peptidoglycan recognition proteins (PGRPs) are
a class of molecules that play a critical role in Dro-
sophila immunity. In this issue of Immunity, Zaid-
man-Re´my et al. (2006) show that PGRP-LB controls
systemic immune responses as well as homeostasis
at the barrier surfaces.
Host defense to microbial challenge in Drosophila relies
on the efficient mounting of an innate immune response,
which is based in part on the induction of antimicrobial
peptides. These cationic peptides are released into the
circulation of the animal and destroy invading microor-
ganisms by disrupting the cell membrane. In the case
of infections by fungi or bacteria, it has been clearly
demonstrated that this humoral response depends
upon the activation of Toll (fungi and gram-positive bac-
teria) and IMD pathways (gram-negative bacteria) (Tanji
and Ip, 2005). Recent understanding of innate immunity
in Drosophila came with the identification of a family of
pattern-recognition receptors, called peptidoglycan
recognition proteins (PGRPs), which are involved in
the detection of bacteria (Tanji and Ip, 2005). PGRPs
are proteins that function upstream of the Toll and
IMD pathways to recognize and bind to peptidoglycan,
a macromolecule present in the cell wall of virtually allbacteria. PGRPs direct the activation of Toll or IMD on
the basis of their ability to discriminate between the
peptidoglycans from either gram-positive or gram-neg-
ative bacteria (Leulier et al., 2003). Indeed, peptidogly-
can from most gram-negative bacteria contains diami-
nopilemic acid (DAP) in the peptide portion of this
complex molecule, while most gram-positive bacterial
peptidoglycan contains lysine (Lys) instead of DAP.
Two PGRPs, termed PGRP-SA and PGRP-SD, detect
gram-positive bacterial-associated Lys-type peptido-
glycan and activate the Toll pathway. On the other hand,
PGRP-LC and PGRP-LE detect the DAP-type peptido-
glycan that is associated most often with gram-negative
bacteria and trigger the IMD pathway (Tanji and Ip,
2005). The activation of these different pathways medi-
ated by PGRPs thereby mounts an antimicrobial re-
sponse that is more or less tailored to the type of
infection.
Strikingly, this concept of recognizing peptidoglycan
based on differences in the stem peptide has been car-
ried over in mammals. The Nod proteins, Nod1 and
Nod2, also detect peptidoglycan, and their sensing
specificities rely on recognizing distinct motifs within
this complex molecule (Girardin et al., 2003). Like
PGRP-LC, Nod1 specifically senses DAP-containing
peptidoglycan and, consequently, is more specific for
sensing gram-negative bacterial infections. Nod2, on
the other hand, can recognize all types of bacteria since
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364Figure 1. PGRP-LB from Drosophila Participates in Balancing the Immune Response: From Maintenance of Homeostasis, to Regulation of Host
Responses, and to Reestablishment of Equilibrium after Infection
PGRP-LB participates at multiple levels of host defense by (A) maintaining homeostasis at epithelial surfaces by degrading peptidogylcan (PG)
and preventing activation of the IMD pathway, (B) activating local and systemic immune responses when the scavenger function is overwhelmed
by PG released from actively dividing bacteria, and (C) downregulating the immune response after infection, by scavenging excess PG and pre-
venting the induction of the IMD pathway. DAP-type PG released from actively dividing gram-negative bacteria activates membrane bound
PGRP-LC, thereby stimulating the IMD pathway. Along with the induction of genes encoding antimicrobial peptides (AMP), this pathway leads
to the induction of PGRP-LB expression allowing for the simultaneous destruction of bacteria through AMP action and degradation of excess PG
through increased circulating PGRP-LB. In this way, PGRP-LB participates in the downregulation of the immune response and reestablishment
of homeostasis.it senses a common substructure of peptidoglycan,
which is called muramyl dipeptide or MDP. However, al-
though it is clear that PGRPs actually bind directly to
peptidoglycan, this issue has not been resolved in the
case of Nod proteins.
Sequence analyses of the 13 Drosophila PGRPs point
to the existence of two subclasses, namely PGRPs that
can either bind and recognize peptidoglycan or, in addi-
tion to these functions, can also hydrolyze the molecule.
Some PGRPS, including PGRP-SA, SD, LC, and LE, fall
into the sub-class of recognition PGRPs. In contrast, the
other sub-group of PGRPs has the demonstrated or
predicted capacity to catalyze the hydrolysis of the
bond between the sugar moiety and the stem peptide
in the peptidoglycan polymer, so-called amidase activ-
ity. This subclass of PGRPs includes PGRP-SC1A/B,
which have been demonstrated to have amidase activ-
ity, and those that have predicted activity, PGRP-SB1/2,
PGRP-SC2, and PGRP-LB (Tanji and Ip, 2005).
Although a critical role for recognition PGRPs in in-
nate immune defense has been demonstrated both bio-
chemically and genetically, the function of hydrolytic
PGRPs remained uncertain for a number of years. Mell-
roth and colleagues first demonstrated that the hydro-
lysis of gram-negative peptidoglycan by PGRP-SC1B
in vitro results in a digested molecule that has lost
immunostimulatory properties (Mellroth et al., 2003).
This prompted the authors to postulate that hydrolytic
PGRPs may play a role as scavenger molecules, impli-
cated in the termination of the immune response. This
assertion has been recently reinforced by the demon-
stration that GlcNAc-AnhydroMurNAc-TetraDAP (alsoknown as tracheal cytotoxin or TCT) is the minimal pep-
tidoglycan motif that fully reconstitutes IMD activation,
whereas TetraDAP (the peptidic product released by hy-
drolytic PGRPs) is fully inactive (Kaneko et al., 2004;
Stenbak et al., 2004). However, validation of this hypoth-
esis still awaited confirmation in vivo. Zaidman-Re´my
et al. (2006), in this issue of Immunity, characterize
the phenotype of flies in which the expression of a pre-
dicted amidase, PGRP-LB, has been extinguished by si-
lencing RNA. Their results go far beyond the demonstra-
tion of an in vivo scavenger function for PGRP-LB in
innate immune responses. Indeed, their results lead to
the unexpected conclusion that this molecule plays
a role as a master regulator of immune homeostasis at
epithelial surfaces.
Zaidman-Re´my et al. (2006) first demonstrate that
PGRP-LB expression is regulated by the IMD pathway.
Septic injury induced PGRP-LB expression in wild-type
and Toll mutant flies but not flies with mutations in
the IMD pathway. Furthermore, gram-negative bacteria
could induce the rapid synthesis and secretion of PGRP-
LB from the fat body. Following this observation, the
authors were then interested in determining the specific-
ity of PGRP-LB toward peptidoglycan. Using an in vitro
approach, PGRP-LB was shown to possess amidase
activity specific for DAP-type peptidoglycan, cleaving it
into fragments that could no longer stimulate an immune
response. These findings show that PGRP-LB recognizes
and hydrolyzes gram-negative peptidoglycan and are
suggestive of a scavenger-type function of this PGRP.
The next challenge was to examine the role of PGRP-
LB in the innate immune response in vivo. To this end,
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(RNAi) strategy to specifically knock down expression
of PGRP-LB in adult flies. Flies with knocked down
PGRP-LB expression did not exhibit increased suscep-
tibility to infection after the introduction of gram-nega-
tive bacteria into the body cavity, thus demonstrating
that PGRP-LB was not essential for the induction of
the immune response through the IMD pathway. How-
ever, reduction of PGRP-LB expression resulted in an
enhanced immune response where PGPR-LB knock-
down flies exhibited higher expression of the IMD-spe-
cific antimicrobial peptide diptericin in response to bac-
teria. Moreover, the response was also longer lasting
compared to that of wild-type flies. Importantly, the au-
thors then performed rescue experiments in which re-
combinant PGRP-LB was injected into the hemolymph
of the knockdown flies. In these studies, the authors el-
egantly demonstrate that PGRP-LB, but not catalyti-
cally inactive PGRP-LB, could rescue the phenotype of
the PGRP-LB knockdown flies and return diptericin pro-
files back to wild-type levels after bacterial challenge.
These findings are significant, because they demon-
strate that PGPR-LB plays a key role in downregulating
responses through IMD, which is in agreement with its
in vitro capacity to scavenge gram-negative peptidogly-
can. Furthermore, this provides in vivo proof that not
only the recognition and binding function of PGRP-LB
is necessary for this effect; indeed the catalytic activity
of the enzyme is required for its ability to negatively reg-
ulate the IMD pathway. This is in contrast to other recent
studies in Drosophila on the function of catalytic PGRPs
in vivo, which suggest that the enzymatic activity of cer-
tain PGRPs is dispensable for their scavenger function
(Bischoff et al., 2006; Garver et al., 2006).
The next series of experiments really highlight the key
role of PGRP-LB in controlling IMD pathway activation
both locally and systemically as well as during homeo-
stasis and in conditions of bacterial challenge. In terms
of homeostasis, the authors demonstrate that PGRP-LB
knockdown flies have increased local antimicrobial
peptide expression in a number of epithelia, including
the gut and trachea, suggesting that peptidoglycan re-
leased from the normal flora is normally degraded by
PGRP-LB to prevent IMD activation in the absence of in-
fection. These studies were also extended to show that
PGRP-LB could also suppress immune responses at
the systemic level. Indeed, systemic tolerance to in-
gested bacteria and gram-negative peptidoglycan was
observed in wild-type flies but not those animals with
repressed PGRP-LB expression. These latter animals
showed increased antimicrobial peptide expression in
the fat body after oral challenge of gram-negative bac-
teria or peptidoglycan. Furthermore, oral challenge with
the minimal active fragment of peptidoglycan for the
IMD pathway, TCT, only induced a systemic response
in PGPR-LB knockdown flies. These findings stress
the fact that TCT, which likely crosses the gut barrier,
is not normally stimulatory in wild-type flies, owing to
the role of PGPR-LB as a scavenger molecule.
The findings by Zaidman-Re´my et al. (2006) go be-
yond the demonstration of an in vivo scavenger function
of PGRP-LB. Indeed, these observations can be used to
form a model that helps to explain innate immune ho-
meostasis in Drosophila and the regulation ofantimicrobial responses through the IMD pathway (see
Figure 1). According to this model, activation of the
IMD pathway in the gut by ingested bacteria occurs
through DAP-type peptidoglycan-dependent stimulation
of PGRP-LC. Consequently, any gram-negative bacte-
ria, including those found normally in the alimentary ca-
nal, could potentially stimulate this pathway to trigger
an immune response. However, local stimulation of
the IMD pathway is prevented by the scavenger func-
tion of PGRP-LB, rendering normally stimulatory pepti-
doglycan into inert fragments. The expression of PGRP-
LB in barrier tissues thereby establishes a threshold be-
low which no activation of an immune response can oc-
cur. In conditions in which bacteria are able to prolifer-
ate, however, PGRP-LB then becomes the sensor of
released peptidoglycan because its activity is likely to
be saturable, allowing free fragments to then stimulate
the IMD pathway through PGRP-LC and activate the im-
mune response. The action of PGRP-LB is also impor-
tant during the resolution of infection. Its expression is
regulated by the IMD pathway, and increased amounts
of PGRP-LB can then act to downregulate the immune
response by ‘‘detoxifying’’ stimulatory peptidoglycan
fragments. Therefore, PGRP-LB mediates the balance
between homeostasis and immune activation, modulat-
ing the host response to commensals and potentially
pathogenic bacteria and downregulating immune acti-
vation during the resolution of infection.
Despite their proven role in modulating and/or con-
trolling the innate immune response in Drosophila, the
function of PGRPs in mammals is less clear. Out of
the four mammalian PGRPs, only PGRP-L has amidase
activity. The phenotype of PGRP-L-deficient mice fail to
demonstrate any clear function for PGRP-L in innate im-
munity (Xu et al., 2004). However, this initial character-
ization has relied on the challenge of mice only by the
systemic route. In light of these recent findings by
Zaidman-Re´my et al. (2006), one can now speculate that
a possible function of PGRP-L in mammals may be
to control host-bacterial homeostasis at mucosal
surfaces.
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Alveolar Macrophage
in the Driver’s Seat
Although alveolar macrophages are normally quies-
cent to prevent damaging the alveoli, in this issue
of Immunity, Takabayshi et al. (2006) demonstrate
that alveolar macrophages can self-regulate their
function on demand to mount an appropriate immune
response.
The function of the lung is to allow the uptake of oxygen
and the excretion of carbon dioxide. Gas exchange oc-
curs in lung alveoli, which are made up of thin type I al-
veolar epithelial cells (AECs) and more cuboidal type II
AECs that produce surfactant and have self-renewal
and differentiation potential. Lung capillaries are situ-
ated in close approximation to the type I cells, sepa-
rated only by a 0.2 mm thick fused basement membrane,
allowing the easy diffusion of gas. With its large surface
area, the lung is exposed to many environmental chal-
lenges and is a portal of entry for many pathogens be-
cause the air we breathe is contaminated with infectious
agents, toxic gases, and (fine) particulate matter. The in-
haled microbes and inhaled toxic substances can then
gain easy access to the bloodstream across the delicate
alveolar-capillary membrane. Defense of this barrier is
not easy and needs to be tightly controlled because
too much edema, inflammation, and cellular recruitment
will lead to thickening of the alveolar wall and will jeop-
ardize the diffusion of gases. Considering the large sur-
face area of the respiratory epithelium and the volume of
air inspired on a daily basis, it is remarkable that there is
so little inflammation under normal conditions.
Nonspecific and specific defense mechanisms pro-
tect the lung from environmental pathogens. Coughing
and sneezing as well as the mucociliary blanket remove
most of the larger particulates from the upper airways.
The innate immune system is very well developed in
the deeper parts of the lung and is made up of a humoral
arm (lactoferrins, lyzozyme, surfactant proteins, man-
nose binding lectin, and defensins) and a cellular arm,
consisting mainly of alveolar macrophages that express
numerous pattern recognition receptors for foreign anti-
gen. If these nonspecific mechanisms fail, a highly de-
veloped network of epithelial and alveolar dendritic cells
(DCs) is responsible for mounting the adaptive immune
response. It has been estimated that the pool of alveolar
macrophages can handle up to 109 intratracheallyXu, M., Wang, Z., and Locksley, R.M. (2004). Mol. Cell. Biol. 24,
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injected bacteria before there is ‘‘spillover’’ of bacteria
to DCs and before adaptive immunity is induced (Ma-
cLean et al., 1996).
Macrophages are specialized hematopoietic cells dis-
tributed throughout different tissues of the body where
they play a central role in homeostasis, tissue remodel-
ing, host defense, and the response to foreign materials,
including particulates. One of the key functional charac-
teristics of macrophages is that, depending on their
state of differentiation and microenvironmental factors
they encounter in a particular tissue, they can be specif-
ically modified to have whatever functions needed to
deal most effectively with a particular inciting stimulus.
In the lung, resident alveolar macrophages are continu-
ously encountering inhaled substances due to their ex-
posed position in the alveolar lumen (Figure 1). To avoid
collateral damage to type I and type II cells in response
to harmless antigens, they are kept in a quiescent state,
producing little inflammatory cytokines and displaying
poor phagocytic activity, as evidenced by downregu-
lated expression of the phagocytic receptor CD11b
(Holt, 1978). In addition, alveolar macrophages actively
suppress the induction of adaptive immunity through
their effects on alveolar and interstitial DCs and T cells.
Elegant studies have demonstrated that in vivo elimina-
tion of alveolar macrophages using clodronate-filled li-
posomes leads to overt inflammatory reactions to other-
wise harmless particulate and soluble antigens (Thepen
et al., 1989). Alveolar macrophages adhere closely to
AECs at the alveolar wall and are separated by a distance
of only 0.2–0.5 mm from interstitial DCs. In macrophage-
depleted mice, the DCs have a clearly enhanced anti-
gen-presenting function (Holt et al., 1993). When mixed
with DCs in vitro, alveolar macrophages suppress T cell
activation through release of nitric oxide (mainly in ro-
dents), prostaglandins, interleukin-10 (IL-10), and trans-
forming growth factor-b (TGFb).
Until recently, it was largely unknown how the lung
environment instructs alveolar macrophages to sup-
press innate and adaptive immunity. A few years ago,
an important step forward was made by the finding that
avb6 integrin-deficient mice have activated alveolar
macrophages due to a lack of TGFb activation in the
lung (Morris et al., 2003). This integrin has the potential
to activate latent TGFb by binding to the latency
associated peptide (LAP), an N-terminal inactivating
fragment of TGFb. Takabayshi et al. in this issue of
Immunity further build on these early findings and dem-
onstrate how the avb6 integrin-TGFb axis influences im-
mune homeostasis in the lung (Takabayashi et al., 2006).
